Revenio Group Oyj - Company Announcement

Revenio Group Corporation: Revenio divests its last software business by selling its last non-core company

Revenio Group Corporation, Stock Exchange Release, 7 May 2015 at 12:10

REVENIO DIVESTS ITS SOFTWARE BUSINESS BY SELLING ITS LAST NON-CORE COMPANY

Revenio Group Corporation has sold the entire share capital of Done Software
Solutions Oy (DSS) to Roima Intelligence Oy. DSS, which had been transferred to
discontinued operations, formed part of the Revenio Technology and Services
segment's Software business. In accordance with its strategy, Revenio is
focusing on health technology and has now finalized the related measures by
selling DSS, its last non-core company.

The parties have agreed not to disclose the sale price. The sale of Done
Software Solutions Oy, which was transferred to discontinued operations at the
end of 2014, will not affect Revenio Group Corporation's financial performance
for 2015 or its previously announced profit guidance. It is estimated that the
sale will boost the Group's cash flow by approximately EUR 1.6 million."Done Software Solutions was the last non-strategic company within our Group and
we are happy that we found for DSS and its personnel the right kind of buyer
that will continue to develop its business as part of a larger whole. Now that
we have finalized the divestment of these non-core operations, we can focus all
of our resources on developing our health technology businesses. We aim to
develop even more efficient and easily adopted methods for the early-stage
detection of diseases that are important to public health. The focus of our
screening technology lies in the early detection of glaucoma, osteoporosis, skin
cancer and asthma, and the monitoring of these during the treatment process,"
says Olli-Pekka Salovaara, President and CEO of Revenio Group.

For further information, please contact:
President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
www.revenio.fi

DISTRIBUTION:
NASDAQ OMX Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish health tech group whose core business is in tonometers. The
Revenio Health Tech segment comprises the business operations of Icare Finland
Oy, Revenio Research Oy and Oscare Medical Oy, which specializes in osteoporosis
screening and monitoring. The common denominators of Revenio's business
operations include screening, follow-up and the global need to make cost savings
in health care via preventive measures. Revenio seeks vigorous growth in health
technology, both organically and through acquisitions and mergers. Revenio aims
at developing even more efficient and easily adopted methods for the early-stage
detection of diseases with significance for public health. The focus of
Revenio's screening technology lies on the early detection of glaucoma,
osteoporosis, skin cancer and asthma, and the monitoring of these during the
treatment process.

In 2014, the Revenio Group's net sales totaled MEUR 16.0, with its operating
profit (EBIT) from continuing operations standing at 27.5%. The Revenio Group
Corporation is listed on NASDAQ OMX Helsinki.


[HUG#1919314]